The density of the biofilm layer produced on a plastic surface by 23 clinical isolates and 1 reference strain of slime-positive, coagulase-negative staphylococci was measured following growth in subinhibitory concentrations (sub-MICs) of cefamandole or vancomycin ranging from 2 to 0.008 ,Ig/ml. All strains were susceptible to <2 ,ug of each agent per ml. The mean biofilm density produced by each strain was calculated from a total of eight determinations at each sub-MIC and was compared with the mean bioffilm density of a drug-free control after correcting for differences in growth. The results showed that the density of the bioflim layer produced by 10 (42%) of 24 strains and 13 (54%) of 24 strains was significantly increased (P < 0.006) at one or more sub-MICs of cefamandole or vancomycin, respectively. In contrast, the density of the bioflm produced by 9 (38%) of 24 and 2 (8%) of 24 strains was significantly reduced at one or more sub-MICs of cefamandole and vancomycin, respectively, and the biofilm density of 7 of these strains was decreased only when the sub-MIC was one-half the MIC. The biofilm density of six strains (five versus cefamandole and one versus vancomycin) was both enhanced and reduced by different sub-MICs of the same agent. None of the strains produced a detectable biofllm at or above the MIC for the strain. These data indicate that antimicrobial agents such as cefamandole or vancomycin could potentially enhance the biofilm matrix produced by certain slime-positive, coagulase-negative staphylococci on the surface of a biomedical implant if concentrations of these agents fall below the MIC for the infecting strain.
such as cefamandole or vancomycin could potentially enhance the biofilm matrix produced by certain slime-positive, coagulase-negative staphylococci on the surface of a biomedical implant if concentrations of these agents fall below the MIC for the infecting strain.
Slime-producing (S+), coagulase-negative staphylococci (CONS), especially Staphylococcus epidermidis, frequently cause foreign-body infections of implantable biomedical devices including cardiac valves (8) , intravascular or peritoneal catheters (2, 5, 13, 21) , and cerebrospinal fluid shunts (22) . Although the pathogenesis of implant-associated infections is not entirely clear, it is presumed that organisms infect a device through one of three routes: direct surgical contamination, transient bacteremia, or extra-or intraluminal migration along transcutaneous devices (1) . Infection and subsequent colonization of a biomedical implant can be divided chronologically into several phases consisting of adherence, groWth, and slime production (9, 19) . The first phase, bacterial adherence, appears to be controlled in vitro by hydrophobic or electrostatic surface interactions between CONS and the substratum (12) . Host tissue or plasma proteins deposited on the surfaces of medical implants may be important determinants of bacterial adhesion in vivo, although the addition of plasma or the plasma protein fibronectin to hydrophobic surfaces reduces the adherence of CONS in vitro (12; W. M. Dunne, P. L. Havens, and F. T. Counter, Program Abstr. 29th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 640, 1989) .
The matrix of bacteria, slime, and exogenous factors (collectively termed a biofilm layer) which envelops the surface of a colonized implant anchors S+CONS firmly to the surface of the device (9, 19) and protects adherent bacteria from host defenses (14) . Once a bacterial biofilm has formed on the surface of an implant, therapeutic options are often limited to long-term administration of antimicrobial therapy or removal of the infected device or both (8, 19) . Antimicrobial therapy alone, even with agents demonstrating in vitro efficacy against the offending strain, is seldom an effective means of sterilizing the surface of an infected implant (17) .
Most strains of S+CONS recovered from infected implants are resistant to a broad spectrum of antimicrobial agents, including beta-lactam antibiotics, macrolides, sulfonamides, trimethoprim, chloramphenicol, and the aminoglycosides (2, 7, 8, 22) . With rare exception, most isolates remain susceptible to rifampin and vancomycin. The in vitro activities of narrow-and expanded-spectrum cephalosporins such as cephalothin and cefamandole are variable. Cefamandole has demonstrated good inhibitory activity in vitro against both methicillin-susceptible and methicillin-resistant CONS (10) .
Sterilization of cerebrospinal fluid shunts infected by CONS with vancomycin alone has been reported (22) , but the therapeutic success rate was significantly higher when infecting strains were slime negative or when vancomycin therapy was used in conjunction with partial or complete revision of the shunt. Recent data reported by Frongillo et al. (11) indicate that cefamandole may be efficacious in the treatment of serious infections caused by CONS (methicillin susceptible or resistant), including foreign-body infections. However, the slime phenotype of recovered isolates was not determined in this study.
The inconsistent success of antimicrobial therapy for prosthetic-implant infections may reflect the poor penetration of antibiotics through a biofilm matrix with subsequent exposure of adherent organisms to subinhibitory concentrations (sub-MICs) of potentially effective agents. Previous studies have shown that sub-MICs of certain antimicrobial agents influence (both positively and negatively) the adherence of a variety of microorganisms, including CONS (16, 20 drug-free control by using the two-tailed Student's t test corrected for multiple comparisons by the method of Bonferroni (15) . By using this method of analysis and ATCC 35984 as a control strain, only one discrepant result was observed with vancomycin, but none were observed with cefamandole when the assay was performed on three consecutive days (data not shown). In addition, there were no significant differences in the mean biofilm density between columns of a single plate when the assay was performed in the absence of antimicrobial agents. Following the measurement of biofilm density, all microdilution plates were stained by the method described by Christensen et al. (4) . However, under the conditions described here, the absorbance of stained biofilms often exceeded the threshold of the instrument (1.5 A) and could not be used for comparison.
Susceptibility testing. The MICs of cefamandole and vancomycin for the test strains of CONS were determined by broth microdilution testing according to published guidelines (18) , with cation-supplemented Mueller-Hinton broth. Previous studies had shown that 19 of the 24 S+CONS were resistant to oxacillin (6).
RESULTS
Cefamandole. All strains of S+CONS were susceptible to 2 ,ug or less of cefamandole per ml by microdilution well susceptibility testing. All MICs obtained with supplemented Mueller-Hinton broth were within one doubling dilution of those observed with TSB. None of the S+CONS produced a detectable biofilm layer at or above the MIC for individual strains. The densities of the biofilm produced by 10 (42%) of 24 strains were significantly increased (P < 0.006) at one or more sub-MICs of cefamandole. The greatest increase in biofilm density produced by a single strain (411% of control) corresponded to a cefamandole concentration of 0.06 ,ug/ml. The biofilm produced by one strain of S+CONS was significantly enhanced at all sub-MICs of cefamandole tested. Biofilm enhancement was detected in the greatest number of test strains (seven) at cefamandole concentrations of 0.12 and 0.06 ,ug/ml (Fig. 1) .
The densities of biofilm formed by 9 (38%) of 24 S+CONS
were significantly reduced at one or more sub-MICs of cefamandole. The biofilm layer produced by two strains was significantly decreased at all sub-MICs of cefamandole tested. Cefamandole at a concentration of 0.5 ,ug/ml caused biofilm reduction in the greatest number of strains (five; Fig.  1 ). The densities of biofilm produced by seven S+CONS were significantly reduced only when the sub-MIC of cefamandole equalled one-half the MIC for the strain. 
